MEDP Stock Analysis: Medpace Holdings | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 16.108m USD | 12M Return: 35.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 199M
EPS Trend: 99.3%
Qual. Beats: 4
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medpace Holdings, Inc. (NASDAQ: MEDP) is a Cincinnati-based contract research organization (CRO) founded in 1992 that provides outsourced clinical development services to the pharmaceutical, biotechnology, and medical device industries. The company supports clinical trials across all phases (Phase I through Phase IV) and operates globally, with service coverage spanning North America, Europe, Asia, South America, Africa, and Australia.
Its full-service offering includes clinical trial design, project management, regulatory affairs, clinical monitoring, data management, biostatistics, pharmacovigilance, and new drug application submissions, along with specialized capabilities such as bio-analytical laboratory services, clinical human pharmacology, imaging, and electrocardiography reading support.
As a large-cap stock in the GICS Life Sciences Tools & Services sub-industry, Medpace operates within the broader CRO sector, which provides outsourced R&D and clinical trial management to drug and device developers seeking to reduce fixed costs and accelerate time-to-market for new therapies.
- Backlog growth and book-to-bill ratio signal trial demand
- Biotech funding pressures elevate clinical trial cancellation rates
- Operating margin expansion outpaces larger CRO competitors
| Net Income: 491.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.36 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: -13.84% < 20% (prev -31.35%; Δ 17.51% < -1%) |
| CFO/TA 0.37 > 3% & CFO 752.7m > Net Income 491.5m |
| Net Debt (-382.6m) to EBITDA (602.2m): -0.64 < 3 |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.8m) vs 12m ago -4.65% < -2% |
| Gross Margin: 28.76% > 18% (prev 31.62%; Δ -2.86% > 0.5%) |
| Asset Turnover: 153.3% > 50% (prev 142.0%; Δ 11.34% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: -0.19 (Total Current Assets 1.05b - Total Current Liabilities 1.44b) / Total Assets 2.06b |
| B: -0.25 (Retained Earnings -511.4m / Total Assets 2.06b) |
| C: 0.32 (EBIT TTM 588.0m / Avg Total Assets 1.81b) |
| D: 0.27 (Book Value of Equity 433.9m / Total Liabilities 1.62b) |
| Altman-Z'' = 0.42 = B |
| DSRI: 0.94 (Receivables 441.8m/377.9m, Revenue 2.78b/2.23b) |
| GMI: 1.10 (GM 31.62% / 28.76%) |
| AQI: 0.70 (AQ_t 0.35 / AQ_t-1 0.50) |
| SGI: 1.25 (Revenue 2.78b / 2.23b) |
| TATA: -0.13 (NI 491.5m - CFO 752.7m) / TA 2.06b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of August 02, 2026, the stock is trading at USD 577.11 with a total of 254,810 shares traded. Over the past week, the price has changed by -4.04%, over one month by +8.97%, over three months by +37.85% and over the past year by +35.09%.
Current recommended Stop Loss: 547.30 (which is 5.2% or 1.2 ATR below the current price).
Medpace Holdings has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold MEDP.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 581.8 | 0.8% |
P/E Trailing = 33.9277
P/E Forward = 33.557
P/S = 5.7895
P/B = 37.0919
P/EG = 3.0865
Revenue TTM = 2.78b USD
EBIT TTM = 588.0m USD
EBITDA TTM = 602.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 23.2m USD (from shortTermDebt, last fiscal year)
Debt = 120.1m USD (from shortLongTermDebtTotal, last quarter) (leases 120.1m already included)
Net Debt = -382.6m USD (calculated: Debt 120.1m - CCE 502.7m)
Enterprise Value = 15.7b USD (16.1b + Debt 120.1m - CCE 502.7m)
Interest Coverage Ratio = unknown (Ebit TTM 588.0m / Interest Expense TTM 0.0)
EV/FCF = 21.44x (Enterprise Value 15.7b / FCF TTM 733.5m)
FCF Yield = 4.66% (FCF TTM 733.5m / Enterprise Value 15.7b)
FCF Margin = 26.36% (FCF TTM 733.5m / Revenue TTM 2.78b)
Net Margin = 17.67% (Net Income TTM 491.5m / Revenue TTM 2.78b)
Gross Margin = 28.76% ((Revenue TTM 2.78b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 28.51% (prev 27.78%)
Tobins Q-Ratio = 7.64 (Enterprise Value 15.7b / Total Assets 2.06b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 120.1m)
Taxrate = 17.94% (107.4m / 598.9m)
NOPAT = 482.5m (EBIT 588.0m * (1 - 17.94%))
Current Ratio = 0.73 (Total Current Assets 1.05b / Total Current Liabilities 1.44b)
Debt / Equity = 0.28 (Debt 120.1m / totalStockholderEquity, last quarter 433.9m)
Debt / EBITDA = -0.64 (Net Debt -382.6m / EBITDA 602.2m)
Debt / FCF = -0.52 (Net Debt -382.6m / FCF TTM 733.5m)
Total Stockholder Equity = 446.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.09% (Net Income 491.5m / Total Assets 2.06b)
RoE = 110.1% (Net Income TTM 491.5m / Total Stockholder Equity 446.2m)
RoCE = 94.57% (EBIT 588.0m / Capital Employed (Total Assets 2.06b - Current Liab 1.44b))
RoIC = 95.39% (NOPAT 482.5m / Invested Capital 505.8m)
WACC = 8.52% (E(16.1b)/V(16.2b) * Re(8.58%) + D(120.1m)/V(16.2b) * Rd(0.0%) * (1-Tc(0.18)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -4.63%
[DCF] Terminal Value 77.43% ; FCFF base≈672.0m ; Y1≈770.4m ; Y5≈1.13b
[DCF] Fair Price = 607.6 (EV 16.6b - Net Debt -382.6m = Equity 17.0b / Shares 27.9m; r=8.52% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.28 | EPS CAGR: 28.26% | SUE: 0.84 | # QB: 4
Revenue Correlation: 98.40 | Revenue CAGR: 16.36% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.44 | Chg30d=+3.62% | Revisions=-73% | Analysts=8
EPS current Year (2026-12-31): EPS=17.70 | Chg30d=+3.45% | Revisions=+25% | GrowthEPS=+15.9% | GrowthRev=+12.7%
EPS next Year (2027-12-31): EPS=19.31 | Chg30d=+2.92% | Revisions=+25% | GrowthEPS=+9.1% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -46% (up=2, down=8)